Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

DRUG

RBV

Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (15)

T2N 4Z6

Calgary

T5H 4B9

Edmonton

T6G 2B7

Edmonton

V5Z 1H2

Vancouver

V5Z 1M9

Vancouver

V6Z 2K5

Vancouver

L6R 3J7

Brampton

N6A 5A5

London

K1H 8L6

Ottawa

M5T 2S8

Toronto

M6H 3M1

Toronto

L4L 4Y7

Vaughan

H2L 4P9

Montreal

H2X 0A9

Montreal

G1V 4G2

Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY